




PHARMACEUTICAL 2020

AILERON THERAPEUTICS INC
Rank 251 of 358





PHARMACEUTICAL 2020

AILERON THERAPEUTICS INC Rank 251 of 358

The relative strengths and weaknesses of AILERON THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AILERON THERAPEUTICS INC compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 39% points. The greatest weakness of AILERON THERAPEUTICS INC is the variable Net Income, reducing the Economic Capital Ratio by 78% points.

The company's Economic Capital Ratio, given in the ranking table, is -9.5%, being 46% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	19,550
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,839
Liabilities, Non-Current	4,586
Other Assets	6,628
Other Compr. Net Income	12
Other Expenses	0
Other Liabilities	0
Other Net Income	587
Other Revenues	0
Property and Equipment	295
Research and Development	17,663
Selling, General and Administrative Expense	12,293

Output Variable	Value in 1000 USD
Assets	26,473
Liabilities	10,425
Expenses	29,956
Revenues	0
Stockholders Equity	16,048
Net Income	-29,369
Comprehensive Net Income	-29,363
Economic Capital Ratio	-9.5%